Page 8 - Demo

See the Product Monograph at www.bayer.com/sites/default/fi les/2020-11/nubeqa-pm-en.pdf for important information relating to warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling Bayer Medical Information at 1-800-265-7382.%u00a9 2024 Bayer Inc.%u00ae TM see www.bayer.ca/tm-mcNUBEQA (darolutamide) is indicated for the treatment of:%u2022 Patients with non-metastatic castration resistant prostate cancer (nmCRPC). NUBEQA has not been studied in patients with nmCRPC at low risk of developing metastases. The benefi t and risk profi le in these patients is unknown.%u2022 Patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.Navigate nmCRPC and mCSPC with the confidence of a NUBEQA regimenReview our body of clinical evidence and experience.PP-NUB-CA-0481-1